Repare Therapeutics Reports Proof Of Concept For Lunresertib In Clinic, Initial Monotherapy Data From Phase 1 MYTHIC Clinical Trial And Early Insights From Ongoing Combination Trials
Portfolio Pulse from Happy Mohamed
Repare Therapeutics reports initial proof of concept monotherapy data from its Phase 1 MYTHIC clinical trial evaluating lunresertib, a first-in-class oral PKMYT1 inhibitor in molecularly selected advanced solid tumors. The data show a favorable tolerability profile and preliminary antitumor activity, supporting the development plans for the lunresertib program.
June 07, 2023 | 8:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Repare Therapeutics' Phase 1 MYTHIC clinical trial for lunresertib shows favorable tolerability and preliminary antitumor activity, supporting the development plans for the program.
The positive initial data from the Phase 1 MYTHIC clinical trial for lunresertib demonstrates a favorable tolerability profile and preliminary antitumor activity. This supports the development plans for the lunresertib program, which could potentially lead to increased investor interest and a positive short-term impact on Repare Therapeutics' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100